Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

addiction

- PMLiVE

Avoiding an Authenticity Gap in healthcare communications

Successful companies align their brand with their reputation

- PMLiVE

It’s behind you!

Healthcare IT problems should provide some warning signs for pharma

EU flag

EU launches HIV action plan

Aims to "significantly contribute" to elimination of HIV in EU by 2020

- PMLiVE

AbbVie takes ‘one-size-fits-all’ HCV regimen into phase III

Comes shortly after Gilead wins priority FDA review for its 'pan-genotypic' treatment

- PMLiVE

Boehringer Ingelheim on walking the talk in patient-centricity

UK medical director Professor Klaus Dugi on patient engagement

- PMLiVE

Merck & Co posts positive hepatitis C data

Elbasvir/grazoprevir achieves high cure rates for patients who inject drugs

- PMLiVE

J&J buys firm seeking hepatitis B cure

Acquires Philadelphia-based Novira therapeutics

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

- PMLiVE

Europe’s health information systems to be modernised

Joint EC-WHO work will form a major strand of their renewedcollaboration

Gilead Sciences

Gilead reports positive data on ‘universal’ hepatitis C regimen

Sets sights on regulatory approval for combination therapy 

- PMLiVE

First-ever World Hepatitis Summit calls for national programmes

Follows rise in hepatitis deaths for fifth consecutive year

Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America

Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links